|
Depressive disorder
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
A predicted miR-330-3p target site SNP (rs41305272) in mitogen-activated protein kinase kinase 5 (MAP2K5) mRNA was in LD (d' = 1.0, r(2) = 0.02) with a reported GWAS-identified variant for restless legs syndrome (RLS), a disorder frequently comorbid with anxiety and depression, possibly because of a shared pathophysiology.
|
24436253 |
2014 |
|
Restless Legs Syndrome
|
0.190 |
Biomarker
|
disease |
BEFREE |
Variants in MEIS1, BTBD9, and MAP2K5/SKOR1 confer a significant risk of RLS in a US population.
|
21925394 |
2011 |
|
Restless Legs Syndrome
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
In the German sample, variants in MEIS1 and BTBD9 were associated with RLS in ESRD (P(nom)≤0.004, ORs 1.52 and 1.55), whereas, in the Greek sample, there was a trend for association to MAP2K5/SKOR1 and BTBD9 (P(nom)≤0.08, ORs 1.41 and 1.33).
|
21572129 |
2011 |
|
Restless Legs Syndrome
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
In a genome-wide association study we found highly significant associations between RLS and intronic variants in the homeobox gene MEIS1, the BTBD9 gene encoding a BTB(POZ) domain as well as variants in a third locus containing the genes encoding mitogen-activated protein kinase MAP2K5 and the transcription factor LBXCOR1 on chromosomes 2p, 6p and 15q, respectively.
|
17637780 |
2007 |
|
Restless Legs Syndrome
|
0.190 |
Biomarker
|
disease |
BEFREE |
Restless legs syndrome (RLS) is considered a genetic disease and, following a genome-wide association study conducted in 2007, the mitogen-activated protein kinase 5 (MAP2K5) gene has been regarded as the promising candidate gene for RLS.
|
29422930 |
2018 |
|
Restless Legs Syndrome
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
Genetic risk variants for RLS have recently been identified in two genes, one of them the homeobox gene MEIS1, known to be involved in embryonic development and variants in a second locus containing the genes encoding mitogen-activated protein kinase MAP2K5, and the transcription factor LBXCOR1.
|
18081164 |
2007 |
|
Restless Legs Syndrome
|
0.190 |
Biomarker
|
disease |
BEFREE |
Our results confirmed the association of BTBD9 and MAP2K5/SKOR1 with primary RLS in Chinese population.
|
28329290 |
2017 |
|
Restless Legs Syndrome
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
A predicted miR-330-3p target site SNP (rs41305272) in mitogen-activated protein kinase kinase 5 (MAP2K5) mRNA was in LD (d' = 1.0, r(2) = 0.02) with a reported GWAS-identified variant for restless legs syndrome (RLS), a disorder frequently comorbid with anxiety and depression, possibly because of a shared pathophysiology.
|
24436253 |
2014 |
|
Restless Legs Syndrome
|
0.190 |
Biomarker
|
disease |
BEFREE |
Our findings directly link MEIS1 and SKOR1, two significantly associated genes with RLS and also prioritize SKOR1 over MAP2K5 in the RLS associated intergenic region of MAP2K5/SKOR1 found by GWAS.
|
30111810 |
2018 |
|
Restless Legs Syndrome
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
Restless legs syndrome (RLS) is associated with common variants in three intronic and intergenic regions in MEIS1, BTBD9, and MAP2K5/LBXCOR1 on chromosomes 2p, 6p and 15q.
|
19279021 |
2009 |
|
Obesity
|
0.140 |
GeneticVariation
|
disease |
BEFREE |
rs2241423 was associated with BMI and obesity in two independent European cohorts suggesting a role for MAP2K5 in early weight regulation.
|
22594783 |
2012 |
|
Obesity
|
0.140 |
GeneticVariation
|
disease |
BEFREE |
Eight loci, rs10968576 (BDNF), rs3817334 (MTCH2), rs1558902 (FTO), rs571312 (MC4R), rs543874 (SEC16B), rs987237 (TFAP2B), rs2867125 (TMEM18) and rs7138803 (FAIM2), were previously known obesity susceptibility loci, and the remaining four loci, rs1514175 (TNNI3K), rs206936 (NUDT3), rs4771122 (MTIF3) and rs2241423 (MAP2K5), were newly identified as BMI loci by the GIANT study.
|
22041983 |
2012 |
|
Obesity
|
0.140 |
GeneticVariation
|
disease |
BEFREE |
Association (Bonferroni corrected) of rs543874 near SEC16B and rs2241423 near MAP2K5 had presumably stronger effects on obesity in Chinese children than in Caucasian populations.
|
26800887 |
2016 |
|
Obesity
|
0.140 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for age, sex and multiple testing, MC4R rs17782313, SEC16B rs543874, MAP2K5 rs2241423 and KCTD15 rs11084753 were associated with obesity and obesity-related traits (all P<0.005), with odd ratios ranging from 1.22 to 2.15.
|
25637721 |
2015 |
|
Carcinogenesis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Abnormal intracellular signaling contributes to carcinogenesis and may represent novel therapeutic targets. mitogen/extracellular signal-regulated kinase kinase-5 (MEK5) overexpression is associated with aggressive prostate cancer.
|
18071319 |
2008 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Mitogen/extracellular signal-regulated kinase kinase-5 (MEK5), which belongs to a network of mitogen-activated protein kinase pathways, play a pivotal role in carcinogenesis.
|
21861603 |
2012 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our results establish MEK5 as a key signalling molecule associated with prostate carcinogenesis.
|
12618764 |
2003 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
MEK5 may be one of the Stat3-regulated genes and plays its essential roles in oncogenesis mediated by aberrantly activated Stat3 signaling in breast carcinomatosis and malignancies.
|
15378007 |
2004 |
|
Carcinogenesis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of MEK5 in MCF-7 cells promoted both hormone-dependent and hormone-independent tumorigenesis in vitro and in vivo and conferred endocrine therapy resistance to previously sensitive breast cancer cells.
|
23950888 |
2013 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Mitogen extracellular-signal-regulated kinase kinase 5 (MEK5) plays an important role in promoting cell proliferation and tumorigenesis.
|
27878304 |
2017 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Mitogen/extracellular signal-regulated kinase kinase-5 (MEK5) has been confirmed to play a pivotal role in tumor carcinogenesis and progression.
|
27160304 |
2016 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The depletion of MEK5 by shRNA significantly decreased breast cancer invasion.
|
27878304 |
2017 |
|
Breast Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The results suggest that the MEK5-ERK5 signaling axis via activation of MEF2B and other transcription factors plays an important role in the induction and maintenance of breast cancer cell migration and invasion and thus represents an exploitable target for the pharmacological inhibition of cancer cell metastasis.
|
29713055 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Given the need for new clinical therapeutic targets, our results demonstrate the therapeutic potential of targeting the MEK5-ERK5 pathway in breast cancer.
|
23950888 |
2013 |
|
Breast Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of MEK5 in APO- MCF-7 breast carcinoma cells shows that this MAPK signaling protein represents a potent survival molecule.
|
12219026 |
2002 |